Clinical Trial Update: Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TSR-042 with Bevacizumab and Niraparib in recurrent ovarian cancer has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasm

Drugs mentioned

• Bevacizumab (bevacizumab)
• Niraparib (Niraparib)
• TSR-042 (dostarlimab)

Snippet

Sponsor: Tesaro, Inc. | Conditions: Ovarian Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2023-04-21